MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway
The metastatic cascade is a complex and multistep process with many potential barriers. Recent evidence has shown that microRNAs (miRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). In this study, by comparing the miRNA expression profiles of SPC-A-1sc...
Gespeichert in:
Veröffentlicht in: | Oncogene 2015-01, Vol.34 (4), p.413-423 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The metastatic cascade is a complex and multistep process with many potential barriers. Recent evidence has shown that microRNAs (miRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). In this study, by comparing the miRNA expression profiles of SPC-A-1sci (high metastatic) and SPC-A-1 (weakly metastatic) cells, we demonstrated that the downregulation and function of
miR-193a-3p
and
miR-193a-5p
in NSCLC metastasis and the expression of these miRNAs was suppressed in NSCLC compared with corresponding non-tumorous tissues. Decreased
miR-193a-3p/5p
expression was significantly associated with tumor node metastasis (TNM) and lymph node metastasis. Furthermore, functional assays showed that the overexpression of
miR-193a-3p/5p
inhibited NSCLC cell migration, invasion and epithelial–mesenchymal transition (EMT)
in vitro
and lung metastasis formation
in vivo
. In addition, we discovered that ERBB4 and S6K2 were the direct targets of
miR-193a-3p
and that PIK3R3 and mTOR were the direct targets of
miR-193a-5p
in NSCLC. We also observed that
miR-193a-3p/5p
could inactivate the AKT/mTOR signaling pathway. Thus,
miR-193a-3p/5p
functions as a tumor suppressor and has an important role in NSCLC metastasis through ERBB signaling pathway. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/onc.2013.574 |